phrykt

First Tracks Biotherapeutics, Inc. (TRAX): who owns it and who trades it

As of Nov 16, 2026, TRAX insiders reported 2 open-market sales worth $66.7M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was EcoR1 Capital, LLC (10% owner), with $65M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling First Tracks Biotherapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TRAX

150 funds and institutions reported TRAX shares worth $692M at the end of Q2 2026, about 96% of the company. The largest holder is EcoR1 Capital, LLC with 9.1%.

Funds and institutions (13F) 96%Everyone else 4%

10 largest owners, by share of the company

EcoR1 Capital, LLC9.1%
TCG Crossover Management, LLC8.3%
FMR LLC (Fidelity)5.9%
Affinity Asset Advisors, LLC5.8%
BlackRock, Inc.5.6%
Trails Edge Capital Partners, LP4.3%
Vanguard Capital Management LLC4.2%
Jupiter Topco LLC3.1%
Vestal Point Capital, LP2.9%
Woodline Partners LP2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
EcoR1 Capital, LLC3.17M9.10%$63.9M–
TCG Crossover Management, LLC2.90M8.30%$58.3M–
FMR LLC (Fidelity)2.05M5.89%$41.3M–
Affinity Asset Advisors, LLC2.03M5.82%$40.9M–
BlackRock, Inc.1.96M5.63%$39.5M–
Trails Edge Capital Partners, LP1.51M4.34%$30.5M–
Vanguard Capital Management LLC1.45M4.16%$29.2M–
Jupiter Topco LLC1.09M3.13%$22M–
Vestal Point Capital, LP1.01M2.90%$20.4M–
Woodline Partners LP917,1762.63%$18.5M–
Sanofi821,9172.36%$16.5M–
Morgan Stanley781,5342.24%$15.7M–
683 Capital Management, LLC750,0002.15%$15.1M–
Adage Capital Partners Gp, L.l.c.729,0002.09%$14.7M–
Balyasny Asset Management L.P.714,9482.05%$14.4M–
Geode Capital Management, LLC702,0872.01%$14.1M–
Bank of America Corp647,9621.86%$13M–
Stempoint Capital LP622,7231.78%$12.5M–
Palo Alto Investors LP603,4891.73%$12.1M–
Sofinnova Investments, Inc.565,1991.62%$11.4M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TRAX insiders reported $0 of open-market purchases and $66.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$66.7M
2 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 2, 2026
Filed Sep 4, 2026

Purchases and sales by month

$65M$65MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 2, 2026J. Anthony WareDirectorSale39,265$44.78$1.8MForm 4
Apr 20, 2026EcoR1 Capital, LLC10% ownerSale4.71M$13.81$65MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
EcoR1 Capital, LLC10% owner–$65MApr 20, 2026
J. Anthony WareDirector–$1.8MSep 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TRAX short interest

High short interest. 12.0% of TRAX shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 29%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.06M TRAX shares were sold short, 12.0% of the shares outstanding, down 27.3% from the report before. At the average daily volume of 775,067 shares, buying them all back would take about 6.5 trading days (days to cover).

Shares short, % of all shares

12.0%May 15Oct 3021.1%

Days to cover

6.5May 15Oct 3011.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.06M12.03%-27%775,0676.5
Oct 15, 20266.96M19.47%+34%1.46M4.8
Sep 30, 20265.19M14.53%+15%837,9886.2
Sep 15, 20264.50M12.59%+12%599,9777.5
Aug 31, 20264.03M11.28%+4%556,6857.2
Aug 14, 20263.89M10.89%-2%576,5086.8
Jul 31, 20263.96M11.34%-17%854,1614.6
Jul 15, 20264.77M13.68%+22%1.14M4.2
Jun 30, 20263.91M11.21%+33%818,1824.8
Jun 15, 20262.94M8.42%-24%574,2365.1
May 29, 20263.87M11.10%-1%372,28110.4
May 15, 20263.92M11.22%-3%478,3688.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

First Tracks Biotherapeutics company events

First Tracks Biotherapeutics filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (control). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Oct 20, 2026AgreementFirst Tracks Biotherapeutics, Inc. closed its previously announced private placement of an aggregate 6,106,870 shares of the Company’s common stock, par value $0.001 per share. Filing
  3. Oct 15, 2026AgreementFirst Tracks Biotherapeutics, Inc. entered into a securities purchase agreement with certain third party investors, pursuant to which the Company agreed to issue and sell an aggregate 6,106,870 shares of the Company’s common stock, par value $0.001 per share to the Investors, at a purchase price of… Filing
  4. Oct 13, 2026AnnouncementOn October 12 2026, the Company issued a press release announcing positive topline data from the first Phase 1b cohort of ANB033 in Celiac Disease. Filing
  5. Aug 12, 2026ResultsReleased financial results. Filing
  6. Jun 22, 2026AgreementFirst Tracks Biotherapeutics, Inc., entered into a Sublease Agreement with AnaptysBio, Inc., a Delaware corporation, pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121. Filing
  7. May 14, 2026ResultsReleased financial results. Filing
  8. Apr 20, 2026ControlThe information set forth under Item 1.01 above is incorporated into this Item 5.01 by reference. Filing
  9. Apr 3, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

First Tracks Biotherapeutics financials

Famous investors that hold TRAX

5 of the 50 well-known investors we track reported holding TRAX in their latest 13F filing. The largest position is Ken Griffin's, worth $22.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026624,142$22.1M0.0%+270%
Steve Cohen · Point72 Asset ManagementQ3 2026417,991$14.8M0.0%+2%
Israel Englander · Millennium ManagementQ3 2026246,982$8.8M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202642,700$1.5M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 202626,561$941K0.0%-48%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named TRAX in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Adage Capital Management, L.P.13G5.8%
Nov 12, 2026Adage Capital Management, L.P.13G5.8%
Nov 6, 2026FMR LLC13G/A15.0%
Nov 6, 2026FMR LLC13G/A15.0%
Oct 27, 2026BlackRock, Inc.13G/A7.2%
Oct 27, 2026BlackRock, Inc.13G/A7.2%

Questions about First Tracks Biotherapeutics, Inc. (TRAX) stock

Who owns the most TRAX stock?

The largest reported owner of First Tracks Biotherapeutics, Inc. (TRAX) is EcoR1 Capital, LLC, with 9.1% of the company. In total, 150 funds and institutions reported holding TRAX at the end of Q2 2026, together about 96% of the shares. See the largest owners.

Are TRAX insiders buying or selling?

In the last 12 months, TRAX insiders reported no open-market purchases and 2 sales worth $66.7M. The latest trade was on Sep 2, 2026. See every trade.

What is the short interest in TRAX?

As of Oct 30, 2026, 5.06M TRAX shares were sold short, 12.0% of the shares outstanding, down 27.3% from the report before. At the average daily volume of 775,067 shares, buying them all back would take about 6.5 trading days (days to cover). See the history.

Which famous investors hold TRAX?

5 of the 50 well-known investors we track reported TRAX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $22.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.